CoPharma has licensed rights to Corixa Corp's aminoalkyl glucosaminide4-phosphate cardioprotectant RC.552. Under the terms of the deal, CoPharma will develop and market RC.552 for the treatment and prevention of cardiac disorders, neuronal damage and ischemia-reperfusion injuries in the USA, Canada, Japan, Oceania and certain other countries in Asia, the Middle East and Africa.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze